FT536

DRUG3 trials

Sponsors

Fate Therapeutics, Masonic Cancer Center, University of Minnesota

Conditions

AstrocytomaBreast CancerColorectal CancerFallopian Tube CancerGastroEsophageal CancerGlioblastomaGynecologic CancerHead and Neck Cancer

Phase 1

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

TerminatedNCT05395052

Fate TherapeuticsBreast Cancer, Colorectal Cancer, GastroEsophageal Cancer +4

Start: 2022-05-31End: 2023-08-11Updated: 2023-09-21

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Active, not recruitingNCT06342986

Masonic Cancer Center, University of MinnesotaFallopian Tube Cancer, Gynecologic Cancer, Ovarian Cancer +1

Start: 2024-07-11End: 2027-06-30Updated: 2026-04-02

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

RecruitingNCT07560865

Masonic Cancer Center, University of MinnesotaAstrocytoma, Glioblastoma, Progressive Disease

Start: 2026-04-23End: 2029-06-01Target: 9Updated: 2026-05-01

Related Papers

204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity

Regular and Young Investigator Award Abstracts2022-11-013 citations